Lisanti Capital Growth, LLC Intra Cellular Therapies, Inc. Transaction History

Lisanti Capital Growth, LLC

$344 Million
Q3 2024

A detailed history of Lisanti Capital Growth, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Lisanti Capital Growth, LLC holds 58,115 shares of ITCI stock, worth $4.85 Million. This represents 1.24% of its overall portfolio holdings.

Number of Shares

58,115

Previous 82,875 29.88%

Holding current value

$4.85 Million

Previous $5.68 Million 25.14%

% of portfolio

1.24%

Previous 1.48%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	SELL	$67.99 - $80.84 $1.68 Million - $2 Million	-24,760 Reduced 29.88%	58,115 $4.25 Million
Q2 2024 Jul 31, 2024	BUY	$64.76 - $79.84 $1.92 Million - $2.36 Million	29,590 Added 55.53%	82,875 $5.68 Million
Q1 2024 May 06, 2024	BUY	$64.37 - $75.65 $25,748 - $30,260	400 Added 0.76%	53,285 $3.69 Million
Q4 2023 Feb 06, 2024	BUY	$46.37 - $73.65 $2.45 Million - $3.89 Million	52,885 New	52,885 $3.79 Million
Q2 2023 Aug 11, 2023	BUY	$54.67 - $66.44 $2.69 Million - $3.26 Million	49,140 Added 77.37%	112,650 $7.13 Million
Q1 2023 May 05, 2023	SELL	$43.8 - $56.99 $2.23 Million - $2.91 Million	-51,024 Reduced 44.55%	63,510 $3.44 Million
Q4 2022 Feb 03, 2023	BUY	$44.07 - $54.45 $1.32 Million - $1.63 Million	29,950 Added 35.41%	114,534 $6.06 Million
Q3 2022 Nov 01, 2022	SELL	$42.7 - $59.99 $10.4 Million - $14.6 Million	-243,310 Reduced 74.2%	84,584 $3.94 Million
Q2 2022 Aug 03, 2022	BUY	$43.0 - $65.64 $2.13 Million - $3.25 Million	49,499 Added 17.78%	327,894 $18.7 Million
Q1 2022 May 12, 2022	BUY	$38.74 - $62.09 $10.8 Million - $17.3 Million	278,395 New	278,395 $17 Million

Others Institutions Holding ITCI

# of Institutions

379

Shares Held

84.7M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.87B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lisanti Capital Growth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lisanti Capital Growth, LLC with notifications on news.

Account

Lisanti Capital Growth, LLC Intra Cellular Therapies, Inc. Transaction History